What question did this study set out to answer?

February 27, 2026

Impact of CD19 CAR T-Cell Therapy on Pathogen-Specific Antibody Titers in Lymphoma Patients.

Key Points

This research aims to evaluate the effect of CD19 CAR T-cell therapy on pathogen-specific antibody titers in lymphoma patients.
Measured IgG titers for various pathogens post-CD19 CAR T-cell therapy.
Assessed stability of antibody levels at Day 100.
Compared titers of pneumococcal and Hib IgG before and after therapy.
MeV, MuV, RuV, VZV, and tetanus toxoid IgG levels remained stable after therapy.
Pneumococcal and Hib IgG titers showed marginal declines but no significant reductions.
Humoral immunity was largely preserved, indicating no routine revaccination may be necessary.

Abstract

MeV, MuV, RuV, VZV, and tetanus toxoid IgG remained stable following CD19 CAR T-cell therapy, while pneumococcal and Hib IgG titers showed marginal quantitative declines, without any fourfold reductions. Overall, humoral immunity at Day 100 following CD19 CAR T-cell therapy remained largely preserved. These seroprevalence findings suggest that routine revaccination may not be required in our patient cohort and highlight the importance of patient monitoring to inform revaccination decisions.

Mark Helpful

Bookmark

Relay